PMID- 15202012
OWN - NLM
STAT- MEDLINE
DCOM- 20050207
LR  - 20061115
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 14
IP  - 1
DP  - 2004 Jul
TI  - Molecular therapy versus standard treatment in allergy (Review).
PG  - 3-22
AB  - The increasing knowledge concerning pathomechanism of allergy creates new 
      perspectives for treatment. Standard methods currently applied in allergy act 
      multidirectional, usually being crude and unselective. Moreover, such therapy 
      does not eliminate the cause of hyperresponse reaction and often fails to restore 
      the immunological balance. It is also noteworthy that the conventional therapy 
      frequently affects different tissues not directly involved in allergic reaction 
      and thus it may exert numerous side effects. The hypersensitivity was found to be 
      related to some cytokines network abnormalities. Among cytokines, there are a 
      few, well-recognized factors e.g., interleukin-4 (IL-4), IL-5 and IL-13, which 
      play a pivotal role in allergy. Thus, the major goal for causal allergy treatment 
      should be restoration of the balance in cytokine-mediated regulation of 
      allergen-driven immunological response. It could be achieved by administration of 
      missing cytokines, e.g., interferon-gamma (IFN-gamma) and/or down regulation of 
      excessive one, e.g., IL-4, IL-13. Such a therapy, directed towards only specific, 
      allergy-involved molecules, should not affect the other by-standing particles or 
      reactions. Obviously, a good target for this kind of treatment could be 
      immunoglobulin E (IgE) that is causally related to anaphylactic response. 
      Furthermore, especially promising objectives for molecular therapy seem to be 
      some cytokine receptors and signal transduction pathways and some adhesion 
      molecules. The most recent therapeutical strategies attempting to restore 
      immunological balance in allergy are presented. They include, among others, 
      anti-cytokine antibodies, their soluble receptors, antisense oligonucleotides and 
      small interfering RNA. Although many of these topical methods are still in the 
      trial phase, we suppose they will become a clinical reality in the near future.
FAU - Grzela, Katarzyna
AU  - Grzela K
AD  - Department of Allergology and Pulmonology, Children Hospital, The Medical 
      University of Warsaw, 5 Chalubinskiego Str., PL 02 004 Warsaw, Poland.
FAU - Lazarczyk, Maciej
AU  - Lazarczyk M
FAU - Dziunycz, Piotr
AU  - Dziunycz P
FAU - Milewski, Lukasz
AU  - Milewski L
FAU - Niderla, Justyna
AU  - Niderla J
FAU - Grzela, Tomasz
AU  - Grzela T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Anti-Allergic Agents)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/therapeutic use
MH  - Genetic Engineering
MH  - Humans
MH  - Hypersensitivity/immunology/*therapy
MH  - Immunotherapy/*methods
RF  - 325
EDAT- 2004/06/18 05:00
MHDA- 2005/02/08 09:00
CRDT- 2004/06/18 05:00
PHST- 2004/06/18 05:00 [pubmed]
PHST- 2005/02/08 09:00 [medline]
PHST- 2004/06/18 05:00 [entrez]
PST - ppublish
SO  - Int J Mol Med. 2004 Jul;14(1):3-22.